Aptevo Therapeutics Inc. (APVO): Price and Financial Metrics
Aptevo Therapeutics Inc. (APVO)
Today's Latest Price: $35.74 USD
Updated Jan 27 9:31am
Add APVO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
APVO Stock Summary
- With a year-over-year growth in debt of 683.79%, Aptevo Therapeutics Inc's debt growth rate surpasses 97.23% of about US stocks.
- As for revenue growth, note that APVO's revenue has grown -63.12% over the past 12 months; that beats the revenue growth of merely 3.31% of US companies in our set.
- In terms of volatility of its share price, APVO is more volatile than 98.2% of stocks we're observing.
- Stocks that are quantitatively similar to APVO, based on their financial statements, market capitalization, and price volatility, are MNDO, ICCC, INS, AVEO, and MOSY.
- Visit APVO's SEC page to see the company's official filings. To visit the company's web site, go to aptevotherapeutics.com.
APVO Stock Price Chart Interactive Chart >
APVO Price/Volume Stats
| Current price | $35.74 | 52-week high | $60.00 |
| Prev. close | $36.57 | 52-week low | $2.94 |
| Day low | $35.74 | Volume | 1,234 |
| Day high | $36.33 | Avg. volume | 80,165 |
| 50-day MA | $39.30 | Dividend yield | N/A |
| 200-day MA | $16.00 | Market Cap | 156.51M |
Aptevo Therapeutics Inc. (APVO) Company Bio
Aptevo Therapeutics, a biotechnology company, provides oncology and hematology therapeutics. Its marketed products include WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn; and HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B. The company was spun off from Emergent BioSolutions Inc. in 2016 and is based in Seattle, Washington.
Loading social stream, please wait...